Antivascular agents for non-small-cell lung cancer: current status and future directions

作者：Amir Eitan; Mandoky Laszlo; Blackhall Fiona; Thatcher Nick; Klepetko Walter; Ankersmit Hendrik Jan; Hoda Mir Ali Reza; Ostoros Gyula; Dank Magdolna; Dome Balazs^*

来源：Expert Opinion on Investigational Drugs, 2009, 18(11): 1667-1686.

DOI：10.1517/13543780903336050

• angiogenesis
• antivascular drug
• clinical trial
• non-small-cell lung cancer

Background: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC) survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. Objective: To summarize the current knowledge on antivascular therapy in patients with NSCLC. Method: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. Results/conclusion: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC.

• 出版日期2009-11